Kanghua Bio: It is expected to increase by 22%-30%year-on-year in the first half of 2022

Recently, the A-share listed company Kanghua Bio (code: 300841.SZ) released the semi-annual report performance forecast. The company is expected to increase from January to June 2022, and the net profit attributable to shareholders of listed companies is 308 million to 330 million yuan.Net profit increased by 22.14%to 30.86%year -on -year, and the company's industries were biological products.

The company made the above prediction based on the following reasons: 1. During the reporting period, the company continued to improve operating management efficiency, and the company's independent vaccine product sales revenue and net profit were increased year -on -year; 2. During the reporting period, the impact of deposit interest income on the company's net profit wasAbout 8 million yuan; 3. During the reporting period, the influence of non -recurring profit and loss on the company's net profit was about 90 million yuan.

- END -